Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Vacuolar fusion protein CCZ1 homolog B (CCZ1B) is a guanine nucleotide exchange factor that partners with Mon1A to form the Mon1-CCZ1 complex. This complex activates Rab7A, facilitating early to late endosomal trafficking and lysosome fusion. CCZ1B is located on the lysosomal membrane and is required for the proper function and biogenesis of lysosomes and vesicle trafficking. Its inhibition or genetic knockout blocks infectious entry of viruses (notably Ebola, Marburg, and SARS-CoV-2) by disrupting their ability to transit from early to late endosomes, making it a promising antiviral drug target. Mutations in CCZ1B may contribute to diseases of lysosomal dysfunction, such as Hermansky-Pudlak syndrome, and its broad role in vesicular transport means therapeutic targeting must be approached with caution.
Inhibition of CCZ1 function blocks viral endosomal trafficking, trapping viruses in early endosomes and preventing replication and cell entry
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Vacuolar fusion protein CCZ1 homolog B (CCZ1B).